Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IBEX Limited (IBEX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. As a Nasdaq-listed Bermuda company and emerging growth issuer, IBEX files a range of documents with the U.S. Securities and Exchange Commission that detail its operations, governance, and financial performance.
Key filings include Form 10-K and related annual reports, which present audited financial statements, risk factors, and management’s discussion of results for the fiscal year. Quarterly results and updates are frequently communicated through Form 8-K, where ibex furnishes press releases covering revenue, net income, adjusted net income, adjusted EBITDA, and earnings per share, as well as guidance ranges for future periods.
Investors can also review proxy materials such as the DEF 14A, which describe the board structure, director independence, committee composition, executive compensation programs, long-term incentive plans, and changes in status such as the transition away from controlled company exemptions. Other 8-K filings address governance developments, including the formation of a formal Nominating Committee and related board decisions.
Stock Titan enhances these filings with AI-powered summaries and explanations that highlight important sections, clarify technical language, and surface items that may matter to shareholders, such as governance changes, compensation plans, or capital allocation decisions. Real-time updates from EDGAR ensure that new IBEX filings, including Forms 3, 4, and 5 for insider transactions when available, appear promptly.
Use this page to explore IBEX’s historical and current SEC record, understand how management presents its strategy and performance, and quickly grasp the implications of lengthy documents through AI-generated insights.
IBEX Ltd (IBEX) Form 4 filing discloses two open-market sales by Chief Executive Officer and Director Robert Thomas Dechant on 2 and 3 July 2025. The transactions involved a total of 5,000 common shares sold at $30.00 per share, producing proceeds of roughly $150,000. Following the dispositions, Dechant’s direct ownership declined from 198,633 to 193,633 shares, a reduction of about 2.5% of his previously held stake. No derivative security activity was reported, and the filing was submitted individually on 3 July 2025.
The modest size of the sale relative to Dechant’s remaining holdings suggests routine portfolio management rather than a wholesale change in insider sentiment. Nonetheless, any CEO sale can attract investor attention, particularly when not explicitly tied to a pre-arranged 10b5-1 trading plan (the form does not indicate such a plan was in place).